GHR and metabolic dysfunction-associated steatotic liver disease: Pegvisomant is a Ghr antagonist that has been observed to bind to the Ghr at the cell surface and hence to block this process; yet further investigation is needed to conclude if this molecule is able to change the course of NAFLD (23).